

## Information for use of NIBSC monoclonal antibody panel for meningococcal typing

Specificity	mAb 'name' <sup>1</sup>	Source of mAb <sup>2</sup>	NIBSC hybridoma number <sup>3</sup>	Previous NIBSC order number	Current NIBSC order number	Approximate dilution of reconstituted stock for dot-blot <sup>4</sup>	Approximate dilution of reconstituted stock for whole cell ELISA <sup>4</sup>	Isotype	Reference
Group A	14-1-A	WRAIR 2D7B5B5B2	4039	95/674	95/674	1 in 300	1 in 100	IgG1	Wedeg, E., Caugant, D., Froholm, L. O. and Zollinger, W. D. (1990). <i>J. Clin. Microbiol.</i> 29:1486-1492.
Group B	2-2-B	WRAIR 5C1-3H7	4040	95/750	95/750	1 in 300	1 in 100	IgM	Mandrell, R.E. and Zollinger, W.D.. (1982). <i>J. Immunol.</i> 129:2172-2178. Zollinger, W.D. and Mandrell, R.E.. (1983). <i>Infect. Immun.</i> 40:257-264. Tsang, R.S and Zollinger, W.D. (2005) <i>Clin. Diagn. Lab. Immunol.</i> 12(1) 152-156
Group C	4-2-C	WRAIR 7H9-4	4041	95/678	95/678	1 in 300	1 in 100	IgG3	Tsang, R.S and Zollinger, W.D. (2005) <i>Clin. Diagn. Lab. Immunol.</i> 12(1) 152-156
Group W135	7-1-W	WRAIR 6G9-7	4044	Not previously available	04/246	1 in 100	n/d	IgM	Tsang, R.S and Zollinger, W.D. (2005) <i>Clin. Diagn. Lab. Immunol.</i> 12(1) 152-156
P3.1		NVI MN3C6B	4032	95/680	04/198	1 in 250	1 in 10000	IgG2b	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P2.2a	1-1-P2a	WRAIR 5D4-5	4055	95/682	02/180	1 in 250	1 in 1000	IgG3	Zollinger, W.D., Moran, E.E., Connelly, H., Mandrell, R.E and Brandt, B. (1984). <i>Infect. Immun.</i> 46:260-266.
P2.2b	3-1-P2b	WRAIR 2H10-2	4056	95/684	Cells would not revive. Replaced with mAb from 4034 see below			IgG3	Zollinger, W.D., Moran, E.E., Connelly, H., Mandrell, R.E and Brandt, B. (1984). <i>Infect. Immun.</i> 46:260-266.

Specificity	mAb 'name' <sup>1</sup>	Source of mAb <sup>2</sup>	NIBSC hybridoma number <sup>3</sup>	Previous NIBSC order number	Current NIBSC order number	Approximate dilution of reconstituted stock for dot-blot <sup>4</sup>	Approximate dilution of reconstituted stock for whole cell ELISA <sup>4</sup>	Isotype	Reference
P2.2b		NVI MN2C3B	4034	Not previously available	05/192	1 in 1000	n/d	IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P3.4		NVI MN14G21	4035	95/686	Replaced with 02/308 see below			IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72 Wedge <i>et al.</i> , J Clin Microbiol (1991) 29:1486 and Urwin <i>et al.</i> , Epidemiol. Infect. (1998) 121: 95-101
P3.4	15-1-P4	WRAIR 5DC4C8G8	4058	Not previously available	02/308	1 in 500	1 in 500	IgG2b	Wedge <i>et al.</i> , J Clin Microbiol (1991) 29:1486 and Urwin <i>et al.</i> , Epidemiol. Infect. (1998) 121: 95-101
P3.15	2-1-P15	WRAIR 8B5-5-G9	4061	95/690	02/310	1 in 250	n/d	IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72 Zollinger, W.D., Moran, E.E., Connelly, H., Mandrell, R.E and Brandt, B. (1984). <i>Infect. Immun.</i> 46:260-266.
P3.21	14-1-P21	WRAIR 6B11-F2-C11	4062	95/692	03/182	1 in 250	1 in 5000	IgG2a	Wedge, E., Caugant, D., Froholm, L. O. and Zollinger, W. D. (1991). <i>J. Clin. Microbiol.</i> 29:1486-1492.
P1.1		NVI MN14C2.3	4020	95/694	03/114	1 in 500	1 in 5000	IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.2		NVI MN16C13F4	4021	95/696	02/178	1 in 1000	1 in 1000	IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.3	12-1-P1.3	WRAIR 5G8B2F9	4053	95/698	02/320	1 in 250	1 in 1000	IgG2a	Cruz, C., Pavez, G., Aguilar, E., Garcia, J., Ruiz, S., Vicent, P., Canepa, I., Martinez, M., Boslego, J.W., Zollinger, W.D. and Arthur, J.D. (1990). <i>Epidemiol. Infect.</i> 105:119-126.

Specificity	mAb 'name' <sup>1</sup>	Source of mAb <sup>2</sup>	NIBSC hybridoma number <sup>3</sup>	Previous NIBSC order number	Current NIBSC order number	Approximate dilution of reconstituted stock for dot-blot <sup>4</sup>	Approximate dilution of reconstituted stock for whole cell ELISA <sup>4</sup>	Isotype	Reference
P1.4		NVI MN20B9.34	4022	95/700	02/148	1 in 250	1 in 10 000	IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.5		NVI MN22A9.19	4023	95/702	03/226	1 in 250	1 in 5000	IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.6		NVI MN19D6.13	4024	95/704	03/210	1 in 250	1 in 1000	IgG3	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.7		NVI MN14C11.6	4025	95/706	01/514	1 in 250	1 in 10 000	IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.9		NVI MN5A10F	4026	95/708	05/190	1 in 250	n/d	IgG2a	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.10		NVI MN20F4.17	4027	95/710	03/224	1 in 250	1 in 10 000	IgG2b	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.12		NVI MN21A7.10	4028	95/712	04/122	1 in 125	n/d	IgG3	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.13		NVI MN25H10.75	4063	95/714	03/236	1 in 125	1 in 5000	IgG2a	Wedeg E <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 314-321
P1.14		NVI MN21G3.17	4029	95/716	03/142	1 in 500	n/d	IgG3	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.15		NVI MN3C5C	4030	95/718	02/144	n/d	1 in 1000	IgG3	Wedeg, E. <i>et al</i> (1999) <i>Clin Diagn Lab Immunol</i> 6: 639-642
P1.16		NVI MN5C11G	4031	95/720	01/538	n/d	1 in 1000	IgG2b	Poolman <i>et al.</i> , (1995) <i>Clin. Diagn. Lab. Immunol.</i> 2: 69-72
P1.19	2-1-P1.19	WRAIR 7A2-11	4050	Not previously available	04/248	1 in 250	n/d	IgG3	Wedeg, E. <i>et al</i> (1999) <i>Clin Diagn Lab Immunol</i> 6: 639-642
L3,7,9	9-2-L379	WRAIR 4BE12C10	4047	Not previously available	01/412	n/d	1 in 1000	IgG2a	Moran, E.E.; Brandt, B.L.; Zollinger, W.D. (1994) <i>Infect. Immun.</i> 63: 5290-5295

Specificity	mAb 'name' <sup>1</sup>	Source of mAb <sup>2</sup>	NIBSC hybridoma number <sup>3</sup>	Previous NIBSC order number	Current NIBSC order number	Approximate dilution of reconstituted stock for dot-blot <sup>4</sup>	Approximate dilution of reconstituted stock for whole cell ELISA <sup>4</sup>	Isotype	Reference
fHbp	JAR4	CHORI	4122	Not previously available	09/170	n/d	1 in 5000	IgG2a	J. A. Welsch, R. Rossi, M. Comanducci, D. M. Granoff, J. Immunol. 172, 5606 (2004). P. T. Beernink, C. Lopasso, A. Angiolillo, F. Felici, D. Granoff, Mol. Immunol. (2009)

n/d = not done

WRAIR = Walter Reed Army Institute of Research

NVI = Netherlands Vaccine Institute (previously the RIVM)

**Notes:**

<sup>1</sup> mAb 'name': This was assigned at WRAIR and is the name used in the literature for the WRAIR mAbs .

<sup>2</sup> Source of mAb: This indicates the laboratory where the hybridoma cells were isolated and the hybridoma clone designation (this is also the name used in the literature for the NVI hybridomas).

<sup>3</sup> NIBSC hybridoma stock number: this number was assigned at NIBSC when the hybridoma cells were received and refers to cells rather than antibody.

<sup>4</sup> The dilutions given are for a stock solution of 1 ampoule reconstituted with 1ml water or phosphate buffered saline. The dilutions are given as a guide and reactivity with different meningococcal isolates will vary. The user should determine the best dilution to use in their own experimental system.

For further information please visit the NIBSC website:

[http://www.nibsc.ac.uk/products/biological\\_reference\\_materials/product\\_catalogue/sub\\_category\\_listing.aspx?category=vaccines&subcategory=Meningococal+typing+and+ELISA+reagents](http://www.nibsc.ac.uk/products/biological_reference_materials/product_catalogue/sub_category_listing.aspx?category=vaccines&subcategory=Meningococal+typing+and+ELISA+reagents)

Or contact Caroline Vipond: [caroline.vipond@nibsc.hpa.org.uk](mailto:caroline.vipond@nibsc.hpa.org.uk)